652 related articles for article (PubMed ID: 20142325)
1. Selective serotonin reuptake inhibitors and breast cancer mortality in women receiving tamoxifen: a population based cohort study.
Kelly CM; Juurlink DN; Gomes T; Duong-Hua M; Pritchard KI; Austin PC; Paszat LF
BMJ; 2010 Feb; 340():c693. PubMed ID: 20142325
[TBL] [Abstract][Full Text] [Related]
2. Effect of selective serotonin reuptake inhibitors use on endocrine therapy adherence and breast cancer mortality: a population-based study.
Valachis A; Garmo H; Weinman J; Fredriksson I; Ahlgren J; Sund M; Holmberg L
Breast Cancer Res Treat; 2016 Sep; 159(2):293-303. PubMed ID: 27492739
[TBL] [Abstract][Full Text] [Related]
3. Do selective serotonin receptor inhibitor antidepressants reduce tamoxifen's effectiveness and increase the risk of death from breast cancer?
Pritchard KI
Breast Cancer Res; 2010 Dec; 12 Suppl 4(Suppl 4):S18. PubMed ID: 21172080
[No Abstract] [Full Text] [Related]
4. Breast cancer recurrence risk related to concurrent use of SSRI antidepressants and tamoxifen.
Lash TL; Cronin-Fenton D; Ahern TP; Rosenberg CL; Lunetta KL; Silliman RA; Hamilton-Dutoit S; Garne JP; Ewertz M; Sørensen HT; Pedersen L
Acta Oncol; 2010 Apr; 49(3):305-12. PubMed ID: 20156115
[TBL] [Abstract][Full Text] [Related]
5. Risk of mortality with concomitant use of tamoxifen and selective serotonin reuptake inhibitors: multi-database cohort study.
Donneyong MM; Bykov K; Bosco-Levy P; Dong YH; Levin R; Gagne JJ
BMJ; 2016 Sep; 354():i5014. PubMed ID: 27694571
[TBL] [Abstract][Full Text] [Related]
6. Tamoxifen and Antidepressant Drug Interaction in a Cohort of 16,887 Breast Cancer Survivors.
Haque R; Shi J; Schottinger JE; Ahmed SA; Cheetham TC; Chung J; Avila C; Kleinman K; Habel LA; Fletcher SW; Kwan ML
J Natl Cancer Inst; 2016 Mar; 108(3):. PubMed ID: 26631176
[TBL] [Abstract][Full Text] [Related]
7. Interaction of serotonin reuptake inhibitors with tamoxifen.
Andersohn F; Willich SN
BMJ; 2010 Feb; 340():c783. PubMed ID: 20142323
[No Abstract] [Full Text] [Related]
8. Unjustified prescribing of CYP2D6 inhibiting SSRIs in women treated with tamoxifen.
Binkhorst L; Mathijssen RH; van Herk-Sukel MP; Bannink M; Jager A; Wiemer EA; van Gelder T
Breast Cancer Res Treat; 2013 Jun; 139(3):923-9. PubMed ID: 23760858
[TBL] [Abstract][Full Text] [Related]
9. Active tamoxifen metabolite plasma concentrations after coadministration of tamoxifen and the selective serotonin reuptake inhibitor paroxetine.
Stearns V; Johnson MD; Rae JM; Morocho A; Novielli A; Bhargava P; Hayes DF; Desta Z; Flockhart DA
J Natl Cancer Inst; 2003 Dec; 95(23):1758-64. PubMed ID: 14652237
[TBL] [Abstract][Full Text] [Related]
10. Tamoxifen's protection against breast cancer recurrence is not reduced by concurrent use of the SSRI citalopram.
Lash TL; Pedersen L; Cronin-Fenton D; Ahern TP; Rosenberg CL; Lunetta KL; Silliman RA; Hamilton-Dutoit S; Garne JP; Ewertz M; Sørensen HT
Br J Cancer; 2008 Aug; 99(4):616-21. PubMed ID: 18665165
[TBL] [Abstract][Full Text] [Related]
11. CYP2D6 genotype, antidepressant use, and tamoxifen metabolism during adjuvant breast cancer treatment.
Jin Y; Desta Z; Stearns V; Ward B; Ho H; Lee KH; Skaar T; Storniolo AM; Li L; Araba A; Blanchard R; Nguyen A; Ullmer L; Hayden J; Lemler S; Weinshilboum RM; Rae JM; Hayes DF; Flockhart DA
J Natl Cancer Inst; 2005 Jan; 97(1):30-9. PubMed ID: 15632378
[TBL] [Abstract][Full Text] [Related]
12. Tamoxifen and CYP 2D6 inhibitors: caution.
Prescrire Int; 2011; 20(118):182-4. PubMed ID: 21751753
[TBL] [Abstract][Full Text] [Related]
13. SSRIs and tamoxifen. Why condemn fluoxetine?
Jenkinson ML
BMJ; 2010 Mar; 340():c1319. PubMed ID: 20219794
[No Abstract] [Full Text] [Related]
14. The Risk of QTc-Interval Prolongation in Breast Cancer Patients Treated with Tamoxifen in Combination with Serotonin Reuptake Inhibitors.
Hussaarts KGAM; Berger FA; Binkhorst L; Oomen-de Hoop E; van Leeuwen RWF; van Alphen RJ; Mathijssen-van Stein D; de Groot NMS; Mathijssen RHJ; van Gelder T
Pharm Res; 2019 Dec; 37(1):7. PubMed ID: 31845095
[TBL] [Abstract][Full Text] [Related]
15. Interactions between tamoxifen and antidepressants via cytochrome P450 2D6.
Desmarais JE; Looper KJ
J Clin Psychiatry; 2009 Dec; 70(12):1688-97. PubMed ID: 20141708
[TBL] [Abstract][Full Text] [Related]
16. Trends in co-prescribing of antidepressants and tamoxifen among women with breast cancer, 2004-2010.
Dusetzina SB; Alexander GC; Freedman RA; Huskamp HA; Keating NL
Breast Cancer Res Treat; 2013 Jan; 137(1):285-96. PubMed ID: 23149465
[TBL] [Abstract][Full Text] [Related]
17. Re: Active tamoxifen metabolite plasma concentrations after coadministration of tamoxifen and the selective serotonin reuptake inhibitor paroxetine.
Ponzone R; Biglia N; Sismondi P
J Natl Cancer Inst; 2004 Jun; 96(11):883-4; author reply 884-5. PubMed ID: 15173274
[No Abstract] [Full Text] [Related]
18. Selective serotonin reuptake inhibitors and adjuvant tamoxifen therapy: risk of breast cancer recurrence and mortality.
Cronin-Fenton D; Lash TL; Sørensen HT
Future Oncol; 2010 Jun; 6(6):877-80. PubMed ID: 20528223
[No Abstract] [Full Text] [Related]
19. Tamoxifen-SSRIs interaction: clinical manifestations of inhibition and lack of inhibition of CYP2D6.
Appiani F; Carroll BT; Muñoz C; Trecco J
Ann Clin Psychiatry; 2011 May; 23(2):152-3. PubMed ID: 21547277
[No Abstract] [Full Text] [Related]
20. Should CYP2D6 inhibitors be administered in conjunction with tamoxifen?
Zembutsu H; Sasa M; Kiyotani K; Mushiroda T; Nakamura Y
Expert Rev Anticancer Ther; 2011 Feb; 11(2):185-93. PubMed ID: 21342038
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]